Clinical Trial Update: Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter) [Phase 3]

View source ↗

Summary

This entry documents a completed Phase 3 safety study of AVP-923 for involuntary emotional expression disorder (pseudobulbar affect). It involves conditions inc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Parkinson Disease
• Stroke
• Traumatic Brain Injury

Drugs mentioned

• AVP-923

Snippet

Sponsor: Avanir Pharmaceuticals | Conditions: Alzheimer's Disease, Stroke | Phase 3 | Status: COMPLETED